

## Express Mail Mailing Label No. EL653442806US Page 1 of 1

MADE													
FORM PTO - 1449							ATTORNEY DOCKET NO.: MIT-103						
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT							APPLICANT(S): Kawasaki et al.						
							SERIAL NO.: 09/422,999						
							FILING DATE: 10/22/99 GROU				UP N	JP NO.: 1646	
U.S. PATENT DOCUMENTS													
EXAM.	1 1			DATE		NAME			CLASS	SUB CLASS		NG DATE IF ROPRIATE	
INIT.	Al	NUMBER		10-21-86		Conn					04-12-82		
		4,618,598		02-23-99		Marquez et al.				06-13-95			
<b>                                     </b>	A2						102 6. 41.						
FOREIGN PATENT DOCUMENTS													
EXAM. INIT.		DOCUMENT DA NUMBER				UNTRY DE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY		ENGLISH LANG (Y/N)	
1	B2	WO 91/15515	10-	17-91	PCT				04-05-91			Y	
OTHER ART, JOURNAL ARTICLES, ETC.													
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)												
	C33	Bos, J., (1998) "All in the family? New insights and questions regarding interconnectivity of Ras, Rap1 and Ral" The EMBO Journal, Vol. 17; No. 23, pp. 6776-6782.											
1	C34	Coller et al., (1995) "New Antiplatelet Agents: Platelet GPIIb/IIIa Antagonists" Thrombosis and Haemostasis, Vol. 74 (1), pp. 302-308.											
P	C35	Newman et al., (January 1985) "Quantitation of Membrane Glycoprotein IIIa on Intact Human Platelets Using the Monoclonal Antibody, AP-3" <u>Blood</u> , Vol. 65; No. 1, pp. 227-232.											
Y	C36	De Bruyn, (October, 1974) "Rap1 and Ral in signal transduction; The Ras family: molecular switches in signaling cascades," Ras-like small GTPases in platelet biology, University Medical Centre of Utrecht, The Netherlands, Chapter 1; General Introduction											
9	C37	Retrospective Cohort Observational Study" Cancer Investigation, Vol. 8 (5), pp. 451-458.											
EXAMINER DATE CONSIDERED 8-17-05													
	<i>y</i>												